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ABSTRACT  
Regulatory T cells (Tregs) are comprised of a heterogeneous population of cells that play a 
vital role in suppressing inflammation and maintaining immune tolerance. Given the crucial 
role of Tregs in maintaining immune homeostasis, it is probably not surprising that many 
microbial species and their metabolites have the potential to induce Tregs. There is now 
great interest in the therapeutic potential of probiotics and prebiotics based strategies for a 
range of autoimmune disorders. This review will summarise recent findings concerning the 
role of probiotics and prebiotics in induction of Tregs to ameliorate the autoimmune 
conditions. In addition, the article is focused to explain the different mechanisms of Treg 
induction and function by these probiotics and prebiotics, based on the available studies till 
date. The article further proposes that induction of Tregs by probiotics and prebiotics could 
lead to the development of new therapeutic approach towards curbing the autoimmune 
response and as an alternative to detrimental immunosuppressive drugs.  
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1. Introduction 
Human body harbours 100 trillion commensal microbes, exceeding the number of 
host cells by more than 10-fold, with a huge amount of genetic information i.e. 100-fold 
more genes than the human genome. With this enormous pool of genetic information, the 
microbiota may influence human life at many levels, far beyond host immunity and 
metabolic functions [1]. The microbiota is an important factor in human development and 
maintenance of the immune response. Recent studies explaining the interactions between 
microbiota and the host immune system have revealed the fundamental importance of the 
microbiome in shaping host immune responses [2].  
Immune aberrations leading to undesirable response to body are major 
considerations for the therapeutic targets of many autoimmune diseases. However, 
approaches leading to less side effects and the effective targetness, avoiding the alteration 
of normal functions of body are a way fŽƌǁĂƌĚ ?/ŶƚŽĚĂǇ ?ƐƐĐĞŶĂƌŝŽƚŚĞĂƉƉƌŽĂĐŚĨor 
controlling the immune hyper-response mainly involves the natural ways which do not 
cause any side effects and help the body to maintain the immune homeostasis. One of such 
approaches includes use of probiotics with conjunction of prebiotics. The term probiotic 
refers to living microorganisms which, when consumed in adequate amounts, confer health 
benefits to the host [3]. A prebiotic is a selectively fermented ingredient that allows specific 
changes, both in the composition and/or activity in the gastrointestinal microflora that 
confers benefits upon host well being and health [4]. The administration of microbes or 
microbial metabolites for the prevention and treatment of aberrant immune response is 
gaining importance [5].  The protective effects associated with these microbes are mediated 
by multiple mechanisms involving T cells, dendritic cells (DCs) and epithelial cells. Recent 
studies have suggested that commensal microbiota is actively involved in the development 
6 
 
of adaptive immune responses by programming many aspects of CD4
+
 T cell differentiation 
[6].  
An increasingly recognised feature of immunoregulatory microbes is their ability to induce 
regulatory T cells (Tregs) [7]. However, the molecular basis of such microbe-mediated 
Treg induction remains partly understood. The induction of Tregs by probiotics is highlighted 
by the amelioration of inflammation and diseases, although it has an effect on several cell 
types including epithelial cells, DCs and T cells. Tregs are a subset of CD4
+
 lymphocytes that 
play a key role in maintaining peripheral tolerance in vivo through the active suppression of 
self-reactive T cell activation and expansion [8]. Thus, these cells are critical towards 
maintaining immune balance and restricting aberrant inflammation [9, 10]. The objective of 
this review article is to highlight the importance of Tregs in autoimmunity and exploring its 
use in curbing the autoimmune diseases through probiotic and prebiotic approaches i.e. 
explaining the impact of probiotic and prebiotic and the associated metabolites on the 
differentiation and function of Tregs. The understanding of these phenomena could provide 
us the insight into the therapeutic and/or preventive strategy for the several autoimmune 
disorders. 
 
2. Regulatory T cells (Tregs) and autoimmunity 
A number of T-cell subsets with immunoregulatory activities have been described, 
and their roles in certain animal autoimmune disease models have been shown and are 
likely to be of relevance in human immune-mediated diseases [11]. Natural Treg cells play a 
key role in maintaining peripheral tolerance in vivo through the active suppression of self-
reactive T-cell activation and expansion (Fig. 1) [12, 13]. These naturally occurring T-cells can 
control actively and dominantly the activation and function of autoreactive T-cells that have 
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escaped from the thymus and can prevent development of the autoimmune diseases (Fig. 
1). Dysfunction or deficiency of Tregs has been reported in several autoimmune diseases, 
both systemic [14, 15] and organ-specific [16]. Recently, the use of Tregs for therapeutic 
purpose in the treatment of autoimmune diseases is gaining importance. In a review article, 
Dwivedi et al., [17] have discussed the therapeutic potential of Tregs in treatment of vitiligo 
(an autoimmune skin depigmenting disorder) including the use of probiotics for the 
induction of Tregs, in addition to adoptive transfer therapy using Tregs, especially heat-
shock protein-specific Tregs. 
There are five major classes of Tregs: thymic derived CD4
+
CD25
+
FoxP3
+
 natural Tregs 
(nTregs), CD4
+
CD25
+
FoxP3
+
 induced Tregs (iTregs), Tr1 type Tregs (IL-10 dependent), Th3 
type Tregs (TGF-ɴĚĞƉĞŶĚĞŶƚ ?>W+) and CD8+ Tregs (Fig. 2) [18]. The most intriguing Tregs 
are those showing CD4
+
CD25
hi
FoxP3
+
 phenotype. FoxP3 has been found to be a specific 
marker for Tregs. CD4
+
CD25
hi
 cells constitute 4-10% whereas CD4
+
CD25
low
 cells comprise 22-
23% of peripheral blood lymphocytes [19, 20]. Inhibition of effector cells proceeds via cell-
cell contact by the former subset and via the secretion of inhibitory cytokines, mainly TGF-ɴ
and IL-10 by the latter. After T-cell receptor (TCR)-mediated stimulation, CD4
+
CD25
hi
FoxP3
+
 
Tregs suppress the activation and proliferation of other CD4
+
 and CD8
+
 T-cells in an antigen 
non-specific manner [21, 22]. Recently, Cortes et al. [23] ŝĚĞŶƚŝĮĞĚĂŶŽǀĞůFoxP3+CD69+ Treg 
subset capable to maintain immune tolerance and protect to developing inflammation. The 
Treg identification, frequently based on the removal of contaminating activated effector T 
cells, includes the expression of the IL1 receptor type I/II (CD121a/CD121b) which has been 
used to distinguish FoxP3
+
 Tregs from activated FoxP3
+
 or FOXP3
-
 effector T cells [24]. 
Similarly, CD49d has been used to identify contaminating activated effector T cells [25]. 
Moreover, the Treg population has also been subdivided according to the expression of 
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inducible co-stimulator (ICOS) [26, 27] and the expression of FoxP3 and CD45RA, a marker of 
naive T cells. FoxP3
high
CD45RA
-
 cells are activated/memory Tregs, positive for Ki-67 ? a 
nuclear protein expressed by proliferating cells [28].  
Other markers expressed by Treg include glucocorticoid-induced tumour necrosis 
factor receptor-related protein (GITR; also known as TNFRSF18, and CD357) and lymphocyte 
activation gene-3 (LAG-3) [29] and CD127 [30]. GITR is expressed at high levels in activated T 
cells and Tregs. However, a recent review article discussing data from mouse and human 
studies has suggested that GITR is a crucial player in the differentiation of thymic Tregs 
(tTregs), and expansion of both tTregs and peripheral Tregs (pTregs) [31]. Moreover, the 
authors have suggested two potential new approaches for treating autoimmune diseases 
consisting of the in vivo expansion of GITR
+
 Tregs by GITR-triggering drugs and in vitro 
expansion of autologous or heterologous GITR
+
 Tregs to be infused in the patients [32]. 
Tregs may also express LAG-3 (CD223), a homolog of the major histocompatibility complex 
(MHC)-II coreceptor, CD4, but with higher binding affinity. The direct interaction of LAG-3 
with MHC-II maintains the immaturity of DCs by reducing MHC-II ?peptide presentation to 
naive T cells [33]. LAG-3 is also required for suppression activity of Tregs as suggested by 
study of Huang et al. [29], in which antibodies to LAG-3 inhibited the suppression by induced 
Tregs both in vitro and in vivo. In addition, natural CD4
+
CD25
+
 Tregs expressed LAG-3 upon 
activation, which was significantly enhanced in the presence of effector cells, whereas 
CD4
+
CD25
+
 Tregs from LAG-3
(-/-)
 mice exhibited a reduced regulatory activity [29]. 
Furthermore, toll like receptors (TLRs), mainly expressed on antigen-presenting cells 
(APC) as a bridge linking innate and adaptive immunity, also exist on Tregs [34]. These Tregs 
play a major role in tuning inflammatory response to infections, in guarding against 
autoimmunity and play a role in tumor progression as well [35]. Moreover, increased 
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CD4
+
CD25
high
FoxP3
+
 Tregs and their involvement in preventing effective antitumor immune 
responses in non-small-ĐĞůůůƵŶŐĐĂŶĐĞƌ ?E^> ?ƉĂƚŝĞŶƚƐ ?[36] suggests that Tregs play a 
critical role in suppressing the activated T cell responses. It is possible that high affinity T-
cells previously escaped clonal deletion in lymph nodes were inadvertently allowed to enter 
the circulation, emigrating to the target cell to inflict damage. An ongoing autoimmune 
response may be allowed to further develop and mature in the absence of functional Tregs 
[37]. In the absence of Tregs, cytotoxic T-cells with increasing affinity for their targets, 
continuously proliferate and migrate towards novel target cells, causing autoimmune 
destruction.  
Though there are several proposed mechanisms with experimental support, yet no single 
mechanism is responsible for the full range of biological phenomena involving Tregs [38]. It 
is likely that in different milieu distinct mechanisms and different alternative subsets of 
regulatory cells are involved in tuning the immune response (Fig. 2) [39]. The putative 
mechanisms of Treg functions are: (i) modulation of antigen-presenting cell (APC) activity 
through Treg engagement of co-stimulatory receptors on the surface of APC, leading to 
weak or abrogated signals from APC to naive/effector cells; (ii) Treg secretion of cytokines, 
such as IL-10 and TGF-ɴ ?ƐƵƉƉƌĞƐƐŝŶŐƚŚĞĂĐƚŝǀŝƚǇŽĨĞĨĨĞĐƚŽƌĐĞůůƐĂŶĚW ? ?ŝŝŝ ?ƵŶĚĞƌĐĞƌƚĂŝŶ
circumstances, Tregs could have a direct cytotoxic effect, through the production of 
perforin/granzyme and induction of apoptosis in effector cells [by the interaction between 
Galectin-9 (Gal-9) and the T cell immunoglobulin and mucin domain-3 (TIM-3)]; (iv) Tregs 
may also cause metabolic disruption, for example stimulating APCs to produce enzymes that 
consume essential amino-acids, preventing naive/effector cell proliferation, and in the 
presence of TGF-ɴŵay induce the expression of FoxP3 in naive cells (i.e., they become 
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Tregs); (v) Tregs could also compete with effectors cells for APC signals or cytokines, such as 
IL-2 [40].  
In recent years, numerous autoimmune and immune-mediated diseases have been shown 
to present significant number depletion and/or function impairment of Tregs. The 
decreased Treg cell numbers and impairment of Tregs function have been reported in 
patients with rheumatoid arthritis (RA) [41], systemic lupus erythematosus (SLE) [42,43,15], 
autoimmune thyroid disease (AITD) [44], multiple sclerosis (MS) [45,46], immune 
thrombocytopenic purpura (ITP) [47] and vitiligo [48-50]. Recently, Quaglino et al. [51] have 
reported a significant down-regulation of circulating Treg cells in a variety of immune-
mediated skin diseases [such as psoriasis, scleroderma, bullous pemphigoid, graft-versus-
host disease (GvHD) and inflammatory bowel disease (IBD)-related dermatoses]. These 
studies suggest for a deregulation of Tregs in maintaining immune homeostasis and 
contributing to immune tolerance breakdown in autoimmunity. 
However, recently, Grant et al. [52] have raised important issues regarding the technical 
challenges associated with studying human Tregs, which have resulted to reports that are at 
times inconsistent or even contradictory and need to be taken care of in future studies 
associated with Tregs. For example, no combination of the different surface markers of Treg 
enables researchers to identify a homogenous Treg population, since the majority of the 
defining markers such as CD25, FOXP3 and CTLA-4 are also increased during effector T cell 
activation. In addition, assays related to evaluate the suppressive capacity of Tregs have also 
been challenged due to small cell numbers as well as different isolation methods implicates 
for Tregs have considerable effects on the study such as their yield, purity, concomitant use, 
and analysis of Treg markers. Moreover, the authors have emphasized that the most 
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profound challenges associated with Treg research is to assess frequency, phenotype or 
function at the site of inflammation [53].  
3. Probiotics and Immune Regulation 
WƌŽďŝŽƚŝĐŝƐĚĞƌŝǀĞĚĨƌŽŵƚŚĞ'ƌĞĞŬǁŽƌĚŵĞĂŶŝŶŐ ‘ƐƵƉƉŽƌƚŝŶŐůŝĨĞ ? and is first 
described as selective non-pathogenic living microorganisms or components of bacteria in 
food supplements, including some commensal bacterial flora, which have beneficial effects 
on host health and disease prevention and/or treatment [54,55]. Metchnikoff [56] first 
suggested that the consumption of lactic acid bĂĐƚĞƌŝĂŵĂǇďĞŶĞĨŝƚƚŚĞŚƵŵĂŶŚŽƐƚ ?Ɛ
immune system. In addition to the major probiotic group of lactic acid bacteria, probiotic 
activity has been found to be associated with Lactobacilli (LGG, gasseri, salivarius), 
Lactococci, Bifidobacteria (bifidum, longum, infantis), Streptococcus (thermophilus, cremoris, 
faecium, infantis), Enterococcus (faecium), non-pathogenic E. coli Nissle 1917, Bacillus 
coagulans and Saccharomyces strains (boulardii and cerevisiae) [56,57]. 
One of the facts is that approximately 70A?ŽĨŽƵƌďŽĚǇ ?ƐŝŵŵƵŶĞƐǇƐƚĞŵŝƐůŽĐĂƚĞĚ
in the gut [58]. Most of the immune system development begins as the baby born and 
continues to mature within a few years of life, when it comes in contact with microbial 
antigens and diets [59]. Important effects of these microorganisms and their products have 
been demonstrated not only in the gut, but also in adipose tissue, immune and nervous 
systems [60-62]. Probiotics in gut do several physiological functions inside the body system, 
mainly metabolic, trophic, and immunologic functions [63]. Gut are loaded with millions and 
trillions of microbes where they degrade undigested carbohydrates to produce important 
immunoregulatory molecules such as short-chain fatty acids (SCFAs) and synthesize 
essential vitamins [64,65]. Moreover, studies with germ-free (GF) animals suggested that 
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the microbiota is necessary for the development and regulation of immunity in the gut 
where it prevents the development of inappropriate inflammation [66-68]. 
Several studies have reported that modifications in the proportions of 
microorganisms in the gut (qualitatively or quantitatively) and, consequently, in the 
concentrations of the compounds produced and released by them in the lumen, play a role 
in the development of pathological conditions including inflammatory bowel disease (IBD), 
colon cancer, and type 1 and 2 diabetes mellitus [61,62,69]. Some of the compounds that 
have been implicated in the effects of microbiota on host cells are microbial-derived ligands 
of toll like receptors (TLRs) such as lipopolysaccharide (LPS) and flagellin, which activate, 
respectively, TLR-4 and -5 and modulate distinct aspects of host metabolism and immune 
responses [68]. Moreover, long term association of commensal microbes within the gut 
make them recognized by the innate immune system as harmless. Commensal microbes 
induce an unusual pattern of maturation of DCs such that these retain the ability to drive 
Treg. Moreover, it is likely that immunoregulatory disorders commonly occur first in those 
individuals whose innate immune systems are least efficient at driving Treg. The increased 
regulatory dendritic cellƐ ?ƌĞŐ ?ĂŶĚdƌĞŐŝŶĚƵĐĞĚďǇ ‘DŝĐƌŽďĞƐƌĞƐŝĚĞŝŶŐƵƚ ?ůĞĂĚƚŽƚǁŽ
immunoregulatory mechanisms mediated in part by release of IL-10 and TGF-ɴ ? Recently, 
Min and Rhee [70] have reviewed the influences of microbiota on the development of the 
gut mucosal immune system which include gut-associated lymphoid tissues (GALT), mucosal 
Barrier, Th17 cells, Tregs, DCs, innate lymphoid cells, IgA-producing B Cells, and plasma 
Cells. In addition, the role of gut microbiota in immune homeostasis and autoimmunity has 
extensively been reviewed by Wu and Wu [71]. 
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4. Prebiotics and Immune Regulation 
One approach to exploit the bacterial communities that influence beneficial immune 
ƌĞƐƉŽŶƐĞŝƐƚŽĨĞĞĚƐƉĞĐŝĨŝĐ ‘substrates ? to the host that would preferentially expand 
beneficial bacteria ? so-called  ‘prebiotics ?. A prebiotic fibre is neither hydrolysed nor 
absorbed in the upper part of the gut, and becomes a selective substrate for one or a 
limited number of beneficial colonic bacteria [72]. Efficient prebiotics need to have a specific 
fermentation therein and thereby have the ability to alter the faecal microflora composition 
ƚŽǁĂƌĚƐĂŵŽƌĞ ‘ďĞŶĞĨŝĐŝĂů ?community structure and impart a role in the immune system 
development and function [73].  Some of the extensively studied prebiotics are fructo-
oligosaccharide (FOS) and inulin. The other prebiotic and fibre associated with immune 
response activation are galacto-oligosaccharides (GOS), lactulose, ressistant starch and 
arabinoxylan-oligosaccharides. 
Short chain fatty acids (SCFAs), which are the major metabolic products of anaerobic 
bacteria fermentation of prebiotic modulate the production of inflammatory mediators by 
macrophages (Fig. 3). In general, SCFAs, such as propionate and butyrate, inhibit stimuli-
induced expression of adhesion molecules, chemokine production and consequently 
suppress monocyte/macrophage and neutrophil recruitment, suggesting an anti-
inflammatory action [74]. SCFAs, mainly butyrate, suppress the LPS- and cytokine-stimulated 
production of pro-inflammatory mediators including TNF-ɲ ?/>-6 and nitric oxide (NO). 
Butyrate also enhances the release of the anti-inflammatory cytokine IL-10 [75,76]. SCFAs 
reduce the in vitro adherence of monocytes and lymphocytes to human umbilical vein 
endothelial cells (HUVEC) [77]. In monocytes, butyrate also reduces the constitutive and 
IFN-ɶ-induced expression of lymphocyte function-associated antigen 3 (LFA-3) and 
intercellular adhesion molecule-1 (ICAM-1) [78]. Moreover, SCFAs regulate several 
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leukocyte functions including production of cytokines (TNF-ɲ ?/>-2, IL-6 and IL-10), 
eicosanoids and chemokines [e.g., MCP-1 (macrophage chemoattractant protein-1) and 
CINC-2(cytokine induce neutrophil chemoattractant-2)]. Studies have reported that the 
concentration of these fatty acids in the gut and blood may predispose to or prevents 
pathological conditions such as IBD, cancer and diabetes [79-81]. SCFAs also modulate the 
production of prostaglandin E2 (PGE2) and have been shown to stimulate the in vitro 
production of this eicosanoid by human monocytes [82]. PGE2 suppresses T cell receptor 
signalling and may play a role in resolution of inflammation [83]. PGE2 has been considered 
an anti-inflammatory prostanoid due to its ability to attenuate the production of IL- ?ɴĂŶĚ
TNF-ɲďǇŵĂĐƌŽƉŚĂŐĞƐĂŶĚdŚ ?ĚŝĨĨĞƌĞŶƚŝĂƚŝŽŶ ?The other SCFAs such as acetate and 
propionate at 30 mM reduce TNF-ɲƉƌŽĚƵĐƚŝŽŶďǇ>W^-stimulated human neutrophils [84]. 
Further, propionate and butyrate have been shown to inhibit the expression of pro-
inflammatory mediators (TNF-ɲ ?/E- ?ɲɴĂŶĚEK ?ŝŶƌĂƚŶĞƵƚƌŽƉŚŝůƐ ?ĂŶĞĨĨĞĐƚƚŚĂƚƐĞĞŵs 
to involve attenuation of NF-ڒB activation [85]. Moreover, the prebiotics such as FOS, GOS, 
inulin and resistant starch have been shown to affect specific probiotic strains that drive the 
induction of Tregs by different mechanisms (Table 2) [86-89]. These reports suggest that 
prebiotics and their metabolites strongly drive the immune cells and their mediators 
towards homeostasis.  
 
5. Mechanisms involved in Treg induction by Probiotics 
Though the knowledge regarding probiotics and their use in mediating the immune 
disorders has expanded in the recent years, its application based approach in treating 
autoimmune disorders has not been extensively appreciated due to the lack of insight into 
the molecular mechanism of their effects on variety of immune cells and its wide 
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consequences. However, their critical role in regulating the regulators of our immune 
system such as  ‘regulatory T cells ? have become recently focused by many research groups. 
Table 1 summarizes the studies which have emphasized the role of several probiotics in 
induction of Tregs and their function by different mechanisms. Few important mechanisms 
with concerning reports are detailed here. 
 
5.1. Activation of Tolerogenic Dendritic Cells (DCs) 
Given the important role of DCs in the orchestration of the immune response, it has 
been hypothesized that probiotic organisms modulate the immune response by influencing 
DC maturation. It has been suggested that some probiotics (L. reuteri and L. casei) influence 
monocyte-derived DCs to drive the development of Treg cells which produced increased 
levels of IL-10 (Fig. 3) [90]. The study suggested that the ability of these probiotics to induce 
Tregs by the DCs is due to their ability to bind to the lectin dendritic cell (DC)-specific 
intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN) (Fig. 3) [90]. In addition, 
extracellular protein such as S-layer protein A (SlpA) secreted by L. acidophilus NCFM has 
been shown to bind DC-SIGN and induce IL-10 production in DCs [91]. Another study also 
showed up-regulation of surface MHC class II and B7-2 (CD86), by Lactobacilli sp. which is 
indicative of DC maturation [92]. Moreover, in an animal model of inflammatory bowel 
disease (IBD), the probiotic VSL #3 (four Lactobacilli, three Bifidobacteria, and one 
Streptococcal strains) reduced the colitis severity due to the production of IL-10, and the 
generation of greater numbers of Treg cells expressing TGF-ɴ[93]. 
Furtheremore, the Bifidobacterium bifidum (B. Bifidum) was found to be most potent 
polarizer in vitro-cultured neonatal DCs to drive Th1-cell responses involving increased IFN-ɶ
producing T cells concomitant with reduction of IL-4-producing T-cells, suggesting its use in 
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prevention of allergic conditions [94,95]. Moreover, T-cells stimulated by B. bifidum resulted 
into matured DCs producing more IL-10 [96]. In addition, Lactobacillus rhamnosus (L. 
rhamnosus) was shown to modulate DC function to induce a novel form of T-cell 
hyporesponsiveness [97]. Another study in mice demonstrated that the probiotic 
preparation VSL #3 increased the expression of B7.1 (CD80), B7.2, CD40 and MHC class II 
molecules. A substantial increase in IL-10 levels was observed in the supernatant when DCs 
were incubated with the probiotics for three days [98]. These results demonstrate that 
probiotics possess the ability to modulate DC surface phenotype and cytokine release by 
blood DCs. In addition, one study showed increased production of IL-10 by murine colonic 
DCs following stimulation with B. longum implicating its important role in Treg induction and 
treatment of intestinal inflammatory diseases [99]. Furthermore, administration of a small 
consortium of probiotic bacteria, containing species of the Lactobacillus, Streptococcus and 
Bifidobacterium genera, upregulated IL-10, TGF-ɴĂŶĚĐǇĐůŽŽǆǇŐĞŶĂƐĞ ? ?Ky ? ?ĞǆƉƌĞƐƐŝŽŶ
in DCs. These regulatory DCs can drive the differentiation of FoxP3
+
 Treg cells, which in turn 
suppress a range of experimental inflammatory states [100].  
These findings suggest that the probiotics act as anti-inflammatory agents by 
influencing DCs to induce a non-response state by promoting the development of Tregs and 
hence may be useful in the treatment of a number of inflammatory diseases, including 
atopic and autoimmune diseases. 
 
5.2. Activation of Treg Associated Molecules 
Specific Treg associated molecules such as Forkhead box P3 (FoxP3), Transforming 
growth factor (TGF)-ɴ ?Cytotoxic T lymphocyte antigen (CTLA)-4, and Interleukin (IL)-10 are 
involved in Treg cell proliferation, development and suppressive functions (Fig. 3). Adequate 
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expression of these molecules leads to induction of Tregs which can curb the effector T cells 
(Teffs) efficiently to prevent the autoimmunity [17]. The transcription factor-FoxP3 is a 
specific marker for Tregs and serves as the dedicated mediator governing Treg cell 
development and function [101]. TGF-ɴŝƐŝŵƉŽƌƚĂŶƚĨŽƌŝŵƉŽƐŝŶŐĂƌĞŐƵůĂƚŽƌǇƉŚenotype 
on the Treg cell subset [102]. Studies have reported that TGF-ɴŚĂƐƚŚĞĂďŝůŝƚǇƚŽŝŶĚƵĐĞ
CD4
+
CD25
-
 cells to become CD4
+
CD25
+
 Tregs in vitro [103,104], and TGF-ɴĐĂŶŝŶĚƵĐĞ&ŽǆW ?
expression in iTregs [105]. Additionally, other studies have clearly demonstrated that the 
suppressive capacity of FoxP3
+
 Tregs in vivo is via a TGF-ɴ-dependent mechanism [106,107]. 
Moreover, Tregs induced by IL-10 contribute to Treg cell-mediated immunosuppression 
principally by producing IL-10 [108]. CTLA-4 (CD152) is a T cell surface molecule involved in 
regulation of T cell activation [109] and plays a critical role in the maintenance of tolerance 
to self-antigens as suggested by knock-out mouse models [110,111].  
Smits et al. [90] reported that L. reuteri and L. casei were involved in DC induced Treg 
cells production with increased levels of IL-10 and these Tregs were capable of inhibiting the 
proliferation of bystander T cells in an IL-10-dependent fashion. The study suggested their 
beneficial effect in the treatment of a number of inflammatory diseases, including atopic 
dermatitis and Crohn's disease. It has been demonstrated that oral consumption of B. 
infantis 35624 is associated with enhanced IL-10 secretion and FoxP3 expression in human 
peripheral blood (Fig. 3) [7]. Murine studies also demonstrated that B. infantis 
administration results in an increase in CD4
+
CD25
+
FoxP3
+
 lymphocytes [112]. Moreover, it 
has been observed that, in vitro human DCs stimulated with B. infantis selectively promoted 
the upregulation of FoxP3 expression in naïve lymphocytes [7] thereby imparting them the 
Treg phenotype. Furthermore, B. infantis has been demonstrated to reduce symptom 
severity in patients with inflammatory bowel syndrome (IBS) in two placebo-controlled 
18 
 
human clinical studies [113,114]. Thus, the induction of FoxP3
+
 Treg cells by B. infantis 
seems to be a robust and reproducible phenomenon, which could be useful in the 
treatment of autoimmune diseases. 
Several studies have provided evidence that probiotics are involved in induction and 
differentiation of IL-10-dependent, TGF-ɴ-bearing Tregs (Fig. 3) [115,116]. It has been 
suggested that probiotic (L. reuteri DSM 17938)-facilitated development of Tregs might play 
an important role in the prevention of necrotising enterocolitis, and Feleszko et al. [117] 
showed that probiotic bacteria (L. rhamnosus GG or B. lactis Bb-12) inhibit subsequent 
allergic sensitisation and airway disease in a murine model of asthma by inducing Tregs 
associated with increased TGF-ɴƉƌŽĚƵĐƚŝŽŶ ?In a food allergy mouse model, oral 
administration of B. bifidum and L. acidophilus suppressed OVA-specific IgE production, 
which was caused by inducing Treg-associated TGF-ɴ production [118]. Kim et al. [119] also 
reported that B. lactis AD011 (BL) increased the production of IL-10 whereas L. casei IBS041 
(LC), and L. acidophilus AD031 (LA) increased TGF-ɴƐĞĐƌĞƚŝŽŶǁŚĞŶŵŽƵƐĞƐǁĞƌĞ
cultured and stimulated with heat-killed probiotic bacteria. A mixture of three Lactobacilli 
strains (L. paracasei DSM 13434, L. plantarum DSM 15312 and DSM 15313) suppressed the 
progression and reversed the clinical and histological signs of experimental autoimmune 
encephalomyelitis by inducing CD4
+
CD25
+
FoxP3
+
 Tregs and enhancing production of serum 
IL-10 and TGF-ɴůĞǀĞůƐ [120]. 
Furthermore, the probiotics mixtures (L. acidophilus, L. casei, L. reuteri, 
ŝĮĚŽďĂĐƚĞƌŝƵŵ, and Streptococcus thermophilus) induced the generation of CD4+FoxP3+ 
Tregs from the CD4
+
CD25
-
 population and increased the suppressor activity of naturally 
occurring CD4
+
CD25
+
 Tregs in mice [100]. Administration of the probiotics mixture induced 
both T-cell and B-cell hyporesponsiveness and down-regulated Th1, Th2, and Th17 cytokines 
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[100]. Interestingly, the report suggests that conversion of T cells into FoxP3
+
 Tregs is 
directly mediated by DCregs that express high levels of IL-10 and TGF-ɴ(Fig. 3). In another 
study, probiotic VSL#3 administration during a remission period ameliorated the severity of 
recurrent colitis in SJL/J mice by inducing an immunoregulatory response involving an early 
increase in the production of IL-10 and TGF-ɴ-bearing T-regs [93]. 
Recently, the effects of L. rhamnosus on the progression of the clinical signs of atopic 
dermatitis to allergic asthma has been shown by suppressing Th2 and Th17 responses via 
CD4
+
CD25
+
FoxP3
+
 Tregs [121]. In addition, the 17 strains belonging to Clostridia clusters IV, 
y/sĂĂŶĚys/// ?ŚĂǀĞďĞĞŶƐŚŽǁŶƚŽŝŶĚƵĐĞd'&ɴ ?ĞǆƉƌĞƐƐŝŽŶďǇŝŶƚĞƐƚŝŶĂůĞƉŝƚŚĞůŝĂůĐĞůůƐ ?
dŚŝƐd'&ɴ ?-rich environment in turn increases the peripheral induction of, and IL-10 
expression by Treg cells, particularly in the colonic mucosa [66,122] suggesting that a range 
of phylogenetically diverse commensal bacteria can suppress intestinal inflammation. Two 
other studies reported that oral administration of a probiotic strain e.g. L. casei could 
increase FoxP3
+
 Tregs and enhance IL-10 and d'&ɴƉƌŽĚƵĐƚŝŽŶ[123,124]. The study 
reported that the strain T120 of lactic acid bacteria was able to inhibit atopic disease in 
NC/Nga mice through enhanced production of IL-10 by spleenocytes and activation of Treg 
cells [123]. Karimi et al. [125] demonstrated that oral L. reuteri treatment increased the 
percentage and total number of CD4
+
CD25
+
FoxP3
+
 T cells in spleens in allergic airway animal 
model which also had greater capacity to suppress T-effector cell proliferation and resulted 
into attenuation of the allergic airway and inflammatory response. A probiotic mix 
containing L. acidophilus and B. longum was also showed to be most effective in prevention 
of trinitrobenzene sulfonic acid (TNBS) induced colitis in BALB/c mice due to expansion of 
Treg cells and increased IL-10 production [126]. Furthermore, one study with VSL#3-treated 
patients with ileal pouch-anal anastomosis showed a significant reduction in ulcerative 
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colitis which was suggested to be due to a significant increase in the percentage of mucosal 
Treg cells [CD4
+
CD25
high
 and CD4
+
LAP-T cells] and a significant increase in FoxP3 mRNA 
expression [127]. 
In another study, a model of allergic contact dermatitis mediated by CD8
+
 cytotoxic T 
lymphocytes and controlled by CD4
+
 Treg cells was reported [128]. Daily oral administration 
of fermented milk containing L. casei or L. casei alone decreased skin inflammation by 
inhibiting the priming/ expansion of hapten-specific IFN-ɶ-producing CD8+ effector T cells. 
This study provides the first evidence that oral administration of L. casei can reduce antigen-
specific skin inflammation by controlling the size of the CD8
+
 effector pool (Fig. 3). 
Moreover, one study where BALB/c mice was sensitized and skin inflammation was induced 
by topical allergen application, suggested that E. coli Nissle 1917 altered the local allergen-
induced immune response (dermatitis) by FoxP3
+
 cell increase and by favouring 
immunoregulatory cytokine patterns [129]. 
Recently, IL-27 has been shown to exert dual effects on Tregs by activating multiple 
signaling cascades, including the JAK-STAT and p38 MAPK pathways and suggested as a 
novel, promising target/agent for the treatment of autoimmune diseases [130]. IL-27 
endows Tregs with IL-10 production and more effective suppression besides facilitating their 
survival and proliferation [131]. These STAT-1 mediated effects are attributable to IL-27-
induced T-bet and CXCR3 coupled with increased IL-10 production in Treg, imparting these 
cells with the ability to control pathogenic Th1 effector responses at local sites [131,132]. IL-
27 can also enhance the suppressive effect of Treg by increasing the expression of CTLA-4 
and PD-1 [133], or LAG3 (on human Treg) [134] on their cell surface. Jeon et al. [135], have 
reported that B. breve activates intestinal CD103
+
 DCs to produce IL-10 and IL-27 via the 
TLR2/MyD88 pathway thereby inducing IL-10-producing Tr1 cells in the large intestine and 
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thus prevents intestinal inflammation. In addition, probiotic strain that favors IL-12 and IL-
27 is likely to skew immune response away from Th17 to Th1 [136]. Several strains of 
Lactobacillus (e.g., L. acidophilus [137], L. gasseri [138], and L. rhamnosus [139]) and 
Bifidobacterium (e.g., B. lactis, B. breve and B. bifidum [140,135]) have been suggested to 
possess this capacity. 
The developmental pathways of Treg and Th17 cells are reciprocally interconnected 
and there is an important plasticity between these cells. Th17 cells represent a pro-
inflammatory subset whereas Treg cells have an antagonist effect. Recently, a review article 
has discussed about Th17/Treg balance to play a major role in the development and the 
disease outcomes of autoimmune diseases [141]. The authors have suggested that targeting 
the Th17/Treg imbalance can be performed at different levels such as inhibition of pro-
inflammatory cytokines and their receptors, of pathogenic cells or their specific signaling 
pathways. One of these mechanisms includes the transcription factors STAT5 and STAT3 
which are known to control the differentiation of Tregs and Th17 cells, respectively. STAT5 
promotes Treg cell development by enhanced expression of FoxP3. Interestingly, the study 
by Miettinen et al. [142] suggested that the extracellular Gram-positive bacteria activate 
transcription factors involved in cytokine signaling by two mechanisms: directly, leading to 
NF-ڒB activation, and indirectly via cytokines, leading to STAT activation. They demonstrated 
that both non-pathogenic L. rhamnosus GG and pathogenic Streptococcus pyogenes (group 
A streptococci) induce NF-ڒB and STAT DNA-binding activity in human primary 
macrophages. Moreover, IL-2 was considered regarding the suppression of Th17 
polarization, and thus regulating the balance between regulatory and inflammatory immune 
cells [143]. More specifically, IL-2 promotes STAT-5 mediated suppression of IL-17 
production while concurrently enabling Treg expansion and survival.  Thus, these signaling 
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pathways could provide novel target molecules for the control of Treg cells in the treatment 
of autoimmune diseases. Interestingly, intake of probiotics (L. bulgaricus and S. 
thermophilus) has been shown to increase IL-2 production by blood lymphocytes [144,145]. 
In addition, L. acidophilus was also shown to increase the number of IL-2 and IL-12 
producing cells [146], suggesting the crucial role of probiotics in induction of Tregs by 
modulating these signaling pathways. 
Overall, these studies have suggested that Treg associated molecules and signaling 
pathways are activated by the probiotics which in turn could able to drive the induction and 
proliferation of active Tregs along with their suppressive functions. Hence, these findings 
open an opportunity to implicate the therapeutic potential of oral administration of a 
combination of probiotics in the management of autoimmune diseases through induction of 
Tregs. However, further animal as well as human studies are required to provide the 
mechanistic and therapeutic details for the possible use of probiotics in autoimmune 
diseases. 
 
5.3. Stimulation of Toll-like Receptors (TLRs) 
Toll-like receptors (TLRs) are a family of pattern recognition receptors present on gut 
lymphoid and epithelial cells that mediates innate immune responses to bacterial molecular 
patterns and, thereby, orchestrates acquired immunity. Marschan et al. [147] suggested 
that the transient protection offered by probiotics against IgE-associated allergic diseases is 
based on stimulation of TLRs. In particular, the findings of the study emphasized the role of 
chronic microbial exposure as an immunomodulator protecting from allergy through 
activation of Treg cells by TLR stimulation [147]. In addition, studies on TLR-2/-3/-4/-7 and -9 
suggested that TLR stimulation could prevent the onset of type 1 diabetes in non-obese 
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diabetes mice and it mediates anti-inflammatory effects of probiotics in murine 
experimental colitis.  [148,149]. The lactic acid bacteria species such as B. bifidum/infantis 
and L. salivarius were shown to be capable of activating TLR-2 [150]. Forsythe et al. [151] 
demonstrated that oral treatment of L. reuteri could drive the activation of TLR-9 which 
resulted into attenuation of asthmatic response in a mouse model of allergic airway 
inflammation. Further the study suggested that the anti-inflammatory response was 
dependent on TLR-9 ?mediated activation of the tolerogenic enzyme indoleamine 2,3-
dioxygenase (IDO). It is suggested that TLR-9 in turn can activate the DCs which induce the 
Tregs. Indeed, DCs expressing IDO contribute to the generation and maintenance of 
peripheral tolerance by depleting autoreactive T cells and by inducing Treg responses [152]. 
Another study performed by Aumeunier et al. [153] on the disease-modifying effects 
of a set of natural or synthetic TLR agonists using two experimental non-obese diabetes 
mouse models, OVA- induced asthma and spontaneous autoimmune type 1 diabetes, 
showed that probiotics stimulate TLR- mediated effects which involve immunoregulatory 
cytokines such as IL-10 and TGF-ɴ and different subsets of Treg cells, notably 
CD4
+
CD25
+
FoxP3
+
 T cells for TLR-4 agonists (Fig. 3).  
Furthermore, Round et al. [154], identified polysaccharide A from the intestinal 
commensal bacterium Bacteroides fragilis, as a bacteria-derived molecule which associated 
with the intestinal epithelium through host mucins and influenced lymphoid organogenesis 
and T cell differentiation to enhance mucosal tolerance which promoted intestinal 
colonization by B. fragilis and suppressed the pathogen-mediated colitis [155]. Moreover, 
Mazmanian  et al. [156] suggested that these immunomodulatory functions depend on the 
expression of polysaccharide A (PSA), which can stimulate DCs through TLR2 [154]. The 
study further reported that FoxP3
+
 CD4
+
 Treg cells produced IL-10 and anti-inflammatory 
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cytokines in response to PSA that was presented by DCs; this also occurs through TLR2 
signalling (Fig. 3) [154]. The findings of these studies suggest that TLRs could be one of the 
potential targets for probiotic mediated induction of the Tregs. 
 
6. Mechanisms involved in Treg induction by Prebiotics 
Several studies have revealed an intricate relationship between Tregs and microbial 
metabolism. Different metabolites and nutrients are produced in the interaction such as 
vitamins, polysaccharides and short chain fatty acids (SCFA). These by products obtained 
during interaction of prebiotics and probiotics regulate Treg generation, trafficking, and 
function through modulating mainly FoxP3 induction and Treg suppressive activity 
[157,158]. 
 
6.1. Short chain fatty acids (SCFAs) in induction of Tregs 
One of the mechanisms by which probiotics maintains immune homeostasis is 
through production of the short-chain fatty acids (SCFAs) such as acetate, propionate, and 
butyrate; generated as end products of the fermentation of dietary fibers (Fig. 3). Several 
studies have provided evidence that SCFAs have beneficial effects on immune regulation 
and prevent inflammatory and autoimmune responses, because the host SCFA receptors 
and target molecules are expressed in immune cells.  Among SCFAs, butyrate has received 
most attention for its effects on colonic health and immune homeostasis [159]. Studies have 
indicated the significant alteration in the number of butyrate-producing bacteria in colon of 
patients with inflammatory disorders [160,161]. Moreover, colonic irrigation with butyrate 
suppressed inflammation during ulcerative colitis [159] suggesting the role of the prebiotics 
in immune regulation. 
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Different bacterial families in the large intestine can produce SCFAs as end products 
of the fermentation of complex carbohydrates such as dietary fiber. One recent study has 
shown that common bacterial metabolites-SCFAs selectively expand Treg cells in the large 
intestine [162]. The study observed that feeding germfree mice three SCFAs (propionate, 
acetate, butyrate), individually or in combination, increased the frequency and number of 
FoxP3 Treg cells in the large intestine to an amount similar to that observed in 
conventionally reared animals. Clostridia species (cluster IV and XIVa) are a prominent 
source of acetate, butyrate, and to a lesser extent propionate in the colon and increase the 
development of Treg cells (those that do not express Helios) by inducing epithelial cells to 
produce TGF-ɴ[122]. It has been suggested that bacterial-driven Treg cell generation in the 
intestine occurs locally and result in Treg cells that do not express the transcription factor 
Helios. The majority of the expanded Treg cell population expressed the Helios, which 
suggests that they acquired FoxP3 expression in the thymus. Interestingly the study 
reported that propionate also increased the expression of FoxP3 and IL-10, but not TGF-ɴŝŶ
colonic Treg cells, indicating that SCFAs can also selectively enhance the Treg cell function. 
In addition, it has been shown that SCFAs inhibits LPS-induced production of TNF-ɲĂŶĚ/&E-
ɶŝŶŚƵŵĂŶWDƐŝŶĂĐŽŶĐĞŶƚƌĂƚŝŽŶ-dependent manner [82]. These reports suggest the 
crucial role of SCFAs in induction of Tregs. Some of the mechanisms of SCFA mediated 
induction of Tregs are discussed here. 
 
6.1.1. SCFAs induction of Tregs by GPR43 and GPR109A expression 
There are distinct pathways through which intestinal bacteria can influence intestinal 
Treg cells (Fig. 3).  One of the pathways involves the cell surface receptors for SCFAs, such as  
G protein-coupled receptors (GPCRs)- GPR43 and GPR109A (also known as 
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hydroxycarboxylic acid receptor 2 or HCA2), which are G protein coupled and are expressed 
in colonic epithelium, adipose tissue, and immune cells [163,164]. Maslowski et al. [62] 
showed that GPR43-deficient mice undergo severe colonic inflammation and colitis in DSS-
induced colitis model and the GPR43 agonist acetate protects germ-free mice from DSS-
induced colitis. Although GPR43 is activated by all three SCFAs, GPR109A (encoded by 
Niacr1) is activated only by butyrate (Fig. 3) [163,165]. In addition to butyrate GPR109A is 
also activated by niacin (vitamin B3) [163,164]. However, in colonic lumen, butyrate is 
generated at high concentrations (10 ?20 mM) by gut microbiota and serves as an 
endogenous agonist for GPR109A [166,167]. Interestingly, Gpr109a in immune cells plays a 
nonredundant function in niacin-mediated suppression of inflammation and atherosclerosis 
[168]. Gut microbiota also produce niacin. Niacin deficiency in humans results in pellagra, 
characterized by intestinal inflammation, diarrhoea, dermatitis, and dementia [169]. It is of 
great clinical relevance that lower abundance of GPR109A ligands, niacin and butyrate in gut 
is associated with colonic inflammation. Recently, Singh et al. [170] have demonstrated an 
anti-inflammatory and anticancer function for Gpr109a in colon. In particular, the study 
observed that butyrate activated Gpr109a signaling imposed anti-inflammatory properties 
in colonic antigen-presenting cells, which in turn induced differentiation of Treg cells and IL-
10-producing T cells suggesting that depletion of gut microbiota or dietary fiber increased 
the risk for inflammatory and autoimmune disorders. 
It is suggested that a combination of Clostridia species (cluster IV and XIVa) 
stimulates local differentiation of Treg cells, whereas administration of SCFAs leads to 
GPR43-dependent accumulation of thymus-derived Treg cell populations. Smith et al. [162] 
reported that propionate showed a superior effect on Treg cell expansion compared to 
acetate and butyrate, which may be due to its higher affinity [171] for GPR43, a receptor for 
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short chain fatty acids [172]. The study showed that intestinal Treg cells also express GPR43 
(primarily expressed by adipocytes, intestinal epithelial cells, and leukocytes), which is 
driven by the presence of bacteria [162]. Interestingly, the observed effect of SCFAs on Treg 
cell expansion was abrogated in mice lacking GPR43 suggestive of its involvement in Treg 
induction through short-chain fatty acids [162]. These reports indicate that these GPCRs 
may regulate the Treg induction by specific SCFA and its concentration modulated by 
prebiotics and probiotics (Fig. 3).  
 
6.1.2. SCFAs induction of Tregs by inhibition of histone deacetylases (HDACs) 
Gene expression is regulated by the modulation of histone acetylation by histone 
acetyl transferases (HATs) and histone deacetylases (HDACs). SCFAs produced by gut 
microbes inhibit HDACs activity and consequently modulate the gene expression (Fig. 3). 
SCFAs function as non-competitive inhibitors of HDACs. Butyrate is the most potent inhibitor 
of HDAC, with a maximum efficiency of approximately 80% inhibition of HDAC1/2, whereas 
acetate is the least potent inhibitor of HDAC [173]. Propionate has a maximum inhibitory 
efficiently of approximately 60%. It has been shown that butyrate and propionate selectively 
inhibit HDAC1 and HDAC3.  The HDACs, together with the HATs, controls the degree of 
protein acetylation. By inhibiting the HDAC activity, SCFAs increase the acetylation of 
histone and non-histone proteins incluĚŝŶŐE&ʃ ?DǇŽ ?Ɖ ? ?ĂŶĚEFAT and, consequently, 
modulate gene expression [174].  
The HDAC inhibition increases the production and suppressive function of FoxP3
+
 
Tregs, at least in part, by promoting the acetylation of FoxP3 protein itself (Fig. 3). FoxP3 
acts as a repressor of transcription and is both an essential and sufficient regulator of the 
development and function of Tregs [175]. Acetylation of FoxP3 is required for effective 
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binding of FoxP3 to the promoter of the interleukin-2 (IL-2) gene and the suppression of IL-2 
expression [176]. Study by Li et al. [175] showed that transcriptional repression by FoxP3 
involves a HAT-HDAC complex that includes histone acetyl transferase TIP60 (Tat-interactive 
protein, 60 kDa) and class II HDACs: HDAC7 and HDAC9. In particular, the N-terminal 106-
190 aa of FoxP3 are required for TIP60-FoxP3, HDAC7-FoxP3 association, as well as for the 
transcriptional repression of FoxP3 via its forkhead domain. FoxP3 can be acetylated in 
primary human Tregs, and TIP60 promotes FoxP3 acetylation in vivo. The HAT-deficient 
mutant and knockdown endogenous TIP60 based experiments suggested that a minimum 
FoxP3 ensemble containing native TIP60 and HDAC7 is necessary for IL-2 production 
regulation in T cells [175]. 
Studies have reported that SCFAs ? mediated HDAC inhibition leads to induction of 
Tregs and its suppressive function (Fig. 3).  Recently, Smith et al. [162] have shown that 
SCFAs such as butyrate are natural inhibitors of HDAC 6 and 9, consistent with the 
promotion of Treg cell generation and function [177]. In addition, recent studies have also 
shown that propionate and butyrate produced by gut microbes promote the generation of 
peripheral Tregs with regard to the inhibition of HDAC [178,179]. Moreover, Furusawa et al. 
[179] have suggested that gut microbe-derived butyrate induces the differentiation of 
colonic Tregs by enhancing histone H3 acetylation in the promoter and conserved non-
coding sequence regions of the FOXP3 locus, and reduces the development of colitis. In 
addition, butyrate, through its HDAC inhibition activity, potentiates the capability of DCs to 
induce Treg differentiation by repressing the expression of LPS response genes [178], and 
also inhibits macrophage activation by rendering them hyporesponsive to TLR stimulation 
[180]. As the inflammatory response is related to the development of several autoimmune 
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diseases, the SCFAs and their target molecules constitute potential therapeutic targets for 
the treatment of these diseases. 
 
6.1.3. SCFAs induction of Tregs by prostaglandin E2 (PGE2) 
SCFAs present multiple effects in different cells involved in the inflammatory and 
immune responses. One of such effects is to modulate the production of PGE2-a key 
mediator in the initiation and resolution of inflammation and in the transition from innate 
to acquired immune responses (Fig. 3) [82,181]. Cox et al. [82] showed that SCFAs can 
induce human monocyte release of PGE2. PGE2 is suggested to play a critical role in 
inflammatory bowel disease (IBD) via the EP4 receptor (i.e. one of the four PGE2 receptor 
subtypes) [182]. 
Prostaglandins are small-molecule derivatives of arachidonic acid (AA), produced by 
cyclooxygenases (COX; constitutively active cyclooxygenase COX1 and inducible COX2) and 
PG synthases [183]. COX enzymes play a critical role in converting arachidonic acid released 
from the cell membrane into prostaglandins.  Perez et al. [184] reported that butyrate 
upregulates Kupffer cell PGE2 production by upregulating inducible COX-2 mRNA levels and 
modulates immune function (Fig. 3). Earlier, elevated levels of PGE2 and COX-2 activity 
leading to induction of Tregs and FoxP3, expansion of Tregs, and enhanced suppressive 
functions have been described (Fig. 3) [185]. Thus, COX2-PGE2-Treg represents an 
immunosuppressive network. 
PGE2 has been shown to promote the development of Tregs in humans and in mice 
(Fig. 3) [185-187]. Interestingly, PGE2 is also involved in mediating the suppressive activity of 
Tregs [188]. It is involved in suppression of T cell receptor signaling [83] and promotes the 
induction of suppressive cytokine IL-10 and to directly suppress the production of multiple 
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proinflammatory cytokines [189]. IL-10 acts as a controller of PGE2 secretion, resulting in 
the paradoxical role of IL-10 in the reversal of the PGE2-mediated macrophage dysfunction. 
In addition to promoting de novo Treg differentiation from naive precursors, PGE2 also 
promotes the interaction of DCs with Tregs [190], suggesting that it may also promote the 
expansion of pre-existing Tregs. Thus, PGE2 can promote the activation, maturation, and 
migration of DCs, the central cells during the development of Ag-specific immunity, and 
suppresses both innate and Ag-specific immunity at multiple molecular and cellular levels 
[189]. Baratelli et al. [191] reported that PGE2 enhances the in vitro inhibitory function of 
human purified CD4
+
CD25
+
 Treg cells and induces a regulatory phenotype in CD4
+
CD25
-
 T 
cells thereby modulating FoxP3 expression and Treg function in human lymphocytes. PGE2 
also induces expansion of Tr1 cells and modulates their activity, thus contributing to 
creating and sustaining a tolerogenic environment [186]. 
A subset of iTreg expressing ectonucleotidases CD39 and CD73 is able to hydrolyze 
dWƚŽ ? ?-AMP and adenosine (ADO) and thus mediate suppression of those immune cells 
which express ADO receptors. iTreg can also produce PGE2. The mechanisms responsible for 
iTreg-mediated suppression involve binding of ADO and PGE2 produced by iTreg to their 
respective receptors expressed on T effector cells (Teff), leading to the up-regulation of 
adenylate cyclase and cAMP activities in Teff and to their functional inhibition [192,193]. 
Thus, targeting the production, degradation, and responsiveness to PGE2 and its regulator 
COX2 may provide tools to modulate the patterns of immunity through Tregs in a wide 
range of inflammatory and autoimmune diseases. 
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6.2. Microbial polysaccharides in induction of Tregs 
Bacteroides fragilis contains an immunomodulatory polysaccharide A (PSA) on its 
outer membrane which is known to increase immunological tolerance through inducing the 
differentiation of FoxP3
+
 Tregs (Fig. 3). B. fragilis-derived PSA engages toll-like receptor 2 
(TLR2) expressed by T cells, which promotes peripheral Treg (pTreg) generation from naive 
CD4
+
 T cells in GALT and peripheral lymphoid organs [154]. In addition, it also enhances Treg 
production of regulatory cytokines including IL-10 and TGF-ɴ2. Moreover, PSA also 
suppresses intestinal IL-17 production and protects against colitis [155]. Studies have 
reported that PSA administration or B. fragilis colonization protects mice from intestinal 
inflammatory diseases [155,194], and ameliorates experimental autoimmune 
encephalomyelitis (EAE), a murine model for human multiple sclerosis (MS) [195,196]. These 
findings suggest that PSA production by B. fragilis induces the generation of Tregs with 
enhanced immunoregulatory activity and protects the host from inflammatory diseases.  
 
6.3. Microbial metabolites generated by the breakdown of food 
Metabolites generated by the breakdown of food by probiotic organisms may have 
immunomodulatory effects. It was demonstrated that L. paracasei NCC2461 participates in 
ƚŚĞɴ-lactoglobulin (BLG) oral tolerance process in mice, attributable to the hydrolysis of 
BLG into peptides, which stimulate the production of IL-10 (Fig. 3) [197,198]. Thus, the 
increased IL-10 production in turn may drive the induction of Tregs in addition to its 
immunosuppressive effects. 
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7. Conclusions 
Given the role of a single bacterial species which can have a drastic impact on host 
immunity, use of probiotics and prebiotics seems to have the positive immuno-ameliorative 
effects for curbing the autoimmunity. In recent years, the immunoregulatory properties of 
probiotics influencing health and disease have emerged as an area of scientific and clinical 
importance. Evidences reveal that the probiotics have a profound effect on the host 
immune system and can affect autoimmune-related diseases. In particular, the ability to 
induce Tregs by different mechanisms, probiotics in conjunction with prebiotics may prove 
to be an effective immunoregulatory approach to suppress autoimmunity. Though, animal 
model studies involving GF (germ free) animals, provides a power tool for such mechanistic 
studies, much more details with animals and human trials is necessary to demonstrate them 
as a successful therapeutic armentarium. The exciting advances and future development 
based on molecular mechanism of immunoregulation by these probiotics may provide new 
opportunities to develop novel Treg-based immunological interventions for the treatment of 
inflammatory and autoimmune diseases. 
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Take-home messages 
x Understanding the interaction of probiotics with the host immune system is 
necessary, especially the regulatory immune system, as the rate of many immune 
disorders are raising at an alarmingly high speed.  
x Several studies have suggested the potential role of probiotics and prebiotics in 
induction of Tregs, however, sufficient human clinical trials are required to confirm 
their role as an effective therapeutics.  
x More intensive investigations are now required to understand the molecular 
mechanisms of Treg induction by probiotics and prebiotics to establish an effective 
immune mediated therapy for autoimmune disorders.  
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Table 1. Induction of regulatory T cells by different mechanisms mediated by probiotics.  
 
Probiotics Different 
Mechanisms for 
Induction of Tregs 
Outcome 
 
Reference 
                                                           I. Development of Tolerogenic Dendritic Cells  
 
Lactobacillus reuteri & 
Lactobacillus casei 
 
Prime monocyte-
derived dendritic 
cell; DC 
maturation 
through up-
regulated surface 
MHC class II and 
B7-2 (CD86) 
Increased Treg cells 
producing increased 
levels of IL-10 
 [90,92] 
 
VSL #3 Matures dendritic 
cells (phenotype 
modulator);  IL-10 
production 
 
Increased production of 
IL-10 by dendritic cells 
and suppression of Th1 
cells; suggested for 
treatment of intestinal 
inflammatory diseases 
 [96,98] 
 
Bifidobacterium bifidum  
 
Prime neonatal 
dendritic cell 
(most potent 
polarizer)  
 
Increased production of 
IL-10 by matured DC; 
suggested in prevention 
or treatment of atopic 
disease.  
 [94,95] 
 
Lactobacillus rhamnosus  Modulates 
dendritic cell 
function (function 
modulator)  
 
Decreased T cell 
proliferation and 
cytokine production (IL-
2, IL-4) by matured DCs 
 [97] 
Bifidobacterium longum Increased IL-10 
production by DC 
 
Suggested  in treatment 
of intestinal 
inflammatory diseases 
 [99] 
                                                            II. Induction of Treg Associated Molecules & Tregs 
 
E. coli Nissle1917 
 
Increased FoxP3
+
 
Tregs  
 
Improved allergen-
induced dermatitis 
 [129] 
 
Probiotic mixture  
 
Increased FoxP3
+
 
Tregs & its 
suppressor activity  
 
Therapeutical effects in 
experimental 
inflammatory bowel 
disease, atopic 
dermatitis, and 
rheumatoid arthritis 
 [100] 
59 
 
Lactobacillus casei DN-114 001 
 
Increased FoxP3
+
 
Tregs, IL-10 & TGF-
ɴƉƌŽĚƵĐƚŝŽŶ 
 
Alleviates antigen-
specific skin 
inflammation; reduced 
arthritis & delayed-type 
hypersensitivity 
 
 [123,124] 
Lactobacillus reuteri & 
Lactobacillus casei 
  
Increased DC-SIGN 
induced Tegs & IL-
10  
Suggested beneficial 
effects in the treatment 
of atopic dermatitis and 
Crohn's disease 
 [90] 
 
VSL#3  
 
Increased IL-10-
dependent TGF-ɴ-
bearing Tregs and 
IL-10 production; 
increased IL-10 
production; 
decreased 
expression of the 
costimulatory 
molecule CD80, 
and decreased 
IFN-ɶ production 
by T cells; 
increased FoxP3
+
 
Tregs 
 
Ameliorate recurrent 
Th1-mediated murine 
colitis; increased anti-
inflammatory effects; 
decreased Pouchitis 
 
[93,96,127] 
Mix 1 (Lactobacillus 
acidophilus & Bifidobacterium 
longum) 
Increased FoxP3
+
 
Tregs and IL-10; 
decreased TNF-ɲ 
Prevention of 
trinitrobenzene sulfonic 
acid (TNBS)-induced 
colitis 
 [126] 
Bifidobacterium infantis 35624 Increased FoxP3
+
 
Tregs; decreased 
TNF-ɲ ?/>-6 
Reduced intestinal 
inflammation 
 [112] 
Lactobacillus paracasei DSM 
13434 & Lactobacillus 
plantarum DSM 15312 
Increased FoxP3
+
 
Tregs, IL-10 & TGF-
ɴƉƌŽĚƵĐƚŝŽŶ 
 
 
Decreased 
experimental 
autoimmune 
encephalomyelitis (EAE) 
[120] 
Bifidobacterium lactis AD011 
& Lactobacillus acidophilus 
AD031  
Increased IL-10; 
decreased IL-4; 
Treg-associated 
TGF-ɴ production  
 
Prevention of allergy 
and atopic dermatits 
 [118,119] 
Bacteroides fragilis FoxP3
+
 Tregs & IL-
10 production  
 
 
Increased  [194] 
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Clostridium sp. (clusters IV and 
XIVa) 
FoxP3
+
 Tregs & 
TGF-ɴ 
Increased  [73] 
Lactobacillus rhamnosus GG 
(ATCC 53103) & 
Bifidobacterium lactis (Bb-12) 
Increased FoxP3
+ 
Tregs and & TGF-ɴ
production 
Suppression of allergic 
sensitization and airway 
inflammation 
 [117] 
Lactobacillus reuteri (ATCC 
23272) 
Increased FoxP3
+
 
Tregs 
Attenuation of allergic 
airway response 
 [125] 
                                                           III. Stimulation of Toll-like Receptors  
 
Bifidobacterium breve  Activation TLR-2 ; 
dendritic cell 
maturation & 
activation; 
increased IL-10 
production 
 
Control of excessive 
Th1 & Th2 polarization 
in atopic newborns 
 [150] 
Lactobacillus reuteri  
 
Activation of TLR-
9; suggestive to 
induce Tregs via 
activation of the 
DCs   
 
Inhibited the allergic 
airway response 
 [151] 
VSL#3  Activation of TLR-3 
and TLR-4; 
increased FoxP3 
Tregs, IL-10 & TGF-
ɴ 
 
Suppressed 
experimental allergic 
asthma and 
autoimmune diabetes 
 [153] 
 
VSL#3: contains 8 different gram-positive organisms (four Lactobacilli, three 
Bifidobacteria, and one Streptococcal strains: Bifidobacterium longum, Bifidobacterium 
infantis, Bifidobacterium breve, Lactobacillus acidophilus, Lactobacillus casei, Lactobacillus 
delbrueckii subsp. bulgaricus, Lactobacillus plantarum, and Streptococcus salivarius subsp. 
thermophilus) 
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Table 2. Induction of regulatory T cells by different mechanisms mediated by prebiotics and 
probiotics. 
 
Prebiotics Effect on 
Probiotic 
Different 
Mechanisms for 
Induction of 
Tregs 
Outcome 
 
Reference 
Fructo-oligosaccharides 
(FOS) 
Increased 
Bifidobacteria 
Increased IL-10 
positive DCs 
expressing TLR2 
and TLR4 
Reduced 
inflammation 
in IBD 
 [86] 
Inulin Increased 
Biofidobacteria, 
Lactobacillus, 
Faecalibacterium 
prausnitzii & 
Eubacterium spp 
Increased IL-10 
positive 
mucosal DCs  
Reduced the 
incidence of 
atopic 
dermatitis 
 [87] 
Resistant starch Increased the 
growth of 
Firmicutes 
Increased 
percentages of 
Tregs in spleen 
and Payer 
Patches 
Reduced 
inflammation 
in IBS 
 [88] 
Ȳ-galactooligosaccharides 
 ?ɴ-GOS) 
Increased 
Bifidobacteria 
Increased the 
production of 
Tregs promoting 
cytokine IL-10 
and significantly 
reduced 
production of IL-
6, IL- ?ɴ ?ĂŶĚ
TNF-ɲ 
Reduced 
inflammation 
in aging 
persons 
 [89] 
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Figure legends 
Fig. 1. Effects of probiotics and prebiotics on immune regulation. Immune homeostasis is 
required to maintain the immune cells in adequate numbers by either their induction or 
suppression. The immune imbalance may lead to increase in particular immune cells 
population such as effector CD8
+
 and CD4
+
 T cells which may not be controlled by a 
deregulated Treg cells with defects in their numbers and/or function. This may lead to 
development of autoimmune conditions exhibiting the several deregulatory immune 
processes such as; increased pro-inflammatory factors, decreased anti-inflammatory 
factors, decreased Treg generation, expansion and activity, decreased tolerogenic DCs, 
increased cytotoxicity (CD8
+
 T cells), increased Th1 activation and proliferation, increased 
Th17 activation, proliferation and increased co-stimulatory activity. However, given the role 
of probiotics and prebiotics in induction of Tregs help in establishing the immune 
homeostasis by increasing the Treg numbers and function which could lead to suppression 
of active CD8
+
 and CD4
+
 T cells. This results in decreased pro-inflammatory factors, 
increased anti-inflammatory factors, increased Treg generation, expansion and activity, 
increased tolerogenic DCs, decreased cytotoxicity (CD8
+
 T cells), decreased Th1 activation 
and proliferation, decreased Th17 activation and proliferation and decreased co-stimulatory 
activity.  
 
Fig. 2. Different types of regulatory T cells and their suppressive functions. Development of 
natural Treg cells (nTregs), naïve CD4
+ 
and CD8
+
 T cells occurs in thymus. These T cells leave 
the thymus for the periphery where they colonize secondary lymphoid tissues and organs. 
nTregs specifically exhibits FoxP3 and CTLA-4 expression whereas naïve CD4
+
 and CD8
+
 T 
cells become inducible Tregs by induction with antigen presenting cells (APCs). These 
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inducible CD4
+
 Tregs are further differentiated into iTreg (induced by IL-2, TGF-ɴ and RA; 
exhibiting increased CD25 and FoxP3 expression), Tr1 (induced by IL-10; exhibiting low CD25 
and no FoxP3 expression) and Th3 (induced by IL-10 and TGF-ɴ; exhibiting no CD25 and 
FoxP3 expression) cells. Tr1 cells secrete high levels of IL-10 and probably TGF-ɴ1 and Th3 
cells secrete high levels of TGF-ɴ1. Other naïve CD4+ T cells differentiate into Th1, Th2 and 
Th17 cells which are induced by IL-12, IL-4 and IL-6, TGF-ɴ respectively. The active 
suppression of these Th1, Th2 and Th17 cells as well as cytotoxic CD8
+
 cells is carried out by 
all three types of inducible CD4
+
 Treg cells by cell-cell contact, secretion of IL-10, TGF-ɴ and 
probably IL-35. Inducible CD8
+
 Treg cells are also developed from naïve CD8
+
 cells by the 
same way as that of CD4
+ 
T cells. These are called as CD4
+
 like CD8
+
 iTregs, Tr1 like CD8
+
 Treg 
and Th3 like CD8
+
 Tregs and mediate the suppression of cytotoxic CD8
+
 T cells and Th1, Th2 
and Th17 cells in the similar manner. nTregs mediate the suppression of cytotoxic  CD8
+
 T 
cells and Th1, Th2 and Th17 cells via cell-cell contact, CTLA-4 and probably by secretion of IL-
10, TGF-ɴ and IL-35. Moreover, CD8+ Treg cells induce the expression of the 
immunoglobulin-like transcripts: ILT3 and ILT4 in APCs, which negatively signal APC function. 
In addition, inducible CD4
+
 Treg cells also inhibit the APC activity by decreasing the co-
stimulatory receptors. nTreg cells via cell-cell contact directly inhibits the inflammatory DCs 
(APCs). nTregs also suppress cytotoxic  CD8
+
 cells by activating IL-10 secreting plasmacytoid 
DCs.  
 
Figure 3. Different mechanisms of Treg induction by probiotics and prebiotics. (i) Probiotics 
induce the release of immunosuppressive cytokines such as TGF-ɴ and IL-10 through TLR 
activation. Moreover, FoxP3 transcription factor along with TGF-ɴ results into Treg induction 
and expansion leading to inhibition of activated CD8
+
 and Th17 cells. (ii) Probiotics bind to 
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the lectin dendritic cell [DC-specific intercellular adhesion molecule 3-grabbing nonintegrin 
(DC-SIGN)] and induce Tregs capable of secreting increased levels of IL-10. (iii) Probiotics 
metabolize the dietary fibers such as resistant starch, inulin, FOS, ɴ-GOS etc. to release 
immunomodulatory short chain fatty acids (SCFAs): acetate, propionate and butyrate. These 
SCFAs activate the G protein-coupled receptors (GPCRs)- GPR43 and GPR109A  on Treg cells. 
GPR43 is activated by all three SCFAs, however, GPR109A is activated only by butyrate. This 
interaction of SCFAs and GPCRs results into induction and expansion of Treg cells capable of 
suppressing the activated CD8
+
 and Th17 cells population by secreting increased amounts of 
IL-10 and TGF-ɴ. Moreover, SCFAs induction also involves inhibition of histone deacetylases 
(HDACs). Butyrate is the most potent inhibitor of HDAC among all three SCFAs. The HDAC 
inhibition increases the production and suppressive function of FoxP3
+
 Tregs by promoting 
the acetylation of FoxP3 protein. In addition, SCFAs modulate the production of 
prostaglandin E2 (PGE2) which is involved in promoting de novo Treg differentiation from 
naive precursors, in suppression of T cell receptor signaling, promoting the induction of 
suppressive cytokine IL-10 and directly suppress the production of multiple proinflammatory 
cytokines. PGE2 also promotes the activation, maturation, and migration of dendritic cells 
(DCs) thereby promotes the interaction of DCs with Tregs and expansion of pre-existing 
Tregs. However, butyrate also induces the increased cyclooxygenase (COX-2) production 
which results into upregulation of PGE2 and affect the immunomodulatory effect of PGE2. 
(iv) Probiotic strain (L. paracasei NCC2461) is involved in hydrolǇƐŝƐŽĨɴ-lactoglobulin (BLG) 
into peptides, which also stimulate the production of IL-10. (v) Microbial polysaccharide 
such as polysaccharide A (PSA) produced by Bacteroides fragilis  induces the differentiation 
of suppressive FoxP3
+
 Treg cells from naïve CD4
+
 T cells through TLR-2 activation. 
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